![Stephen Hiscox](https://profiles-cardiff.imgix.net/attachments/2920?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Overview
I joined the Metastasis Research Group within the University of Wales College of Medicine as a member of research staff in 1993.
I received the American Association for Cancer Research Young Investigators Award in 1998 and, in 1999, attained my PhD and received a University of Wales College of Medicine Senior Research Fellowship in recognition of my contribution to research within the college.
After spending a further 3 years within this group, I joined the Tenovus Centre for Cancer Research in 2001. In 2007, I was awarded an RCUK Academic Fellowship to enable me to pursue my research and teaching interests in the field of cancer invasion and metastasis within the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Promotion to Senior Lecturer in the School followed in 2012.
Qualifications
- PhD, Tumour metastasis, University of Wales College of Medicine (1999)
- BSc (Hons), Biochemistry, Coventry University (1991)
Publication
2021
- Cai, S. et al. 2021. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. International Journal of Oncology 58(6), article number: 34. (10.3892/ijo.2021.5214)
2020
- Rees, M., Smith, C., Barrett-Lee, P. and Hiscox, S. 2020. PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer. Oncotarget 11(51), pp. 4722-4734. (10.18632/oncotarget.27846)
- Kandil, S. B., Jones, S. R., Smith, S., Hiscox, S. E. and Westwell, A. D. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25(15), article number: 3488. (10.3390/molecules25153488)
- Ranganathan, P., Chakrabarty, A., Hiscox, S., Limaye, A. M. and Vella, V. 2020. Editorial: Resistance to endocrine therapies in cancer. Frontiers in Endocrinology 11, article number: 196. (10.3389/fendo.2020.00196)
2018
- Davison, Z., Nicholson, R. I., Hiscox, S. and Heard, C. M. 2018. Co-administration of fish oil with signal transduction inhibitors has anti-migration effects in breast cancer cell lines, in vitro. The Open Biochemistry Journal 12(1), pp. 130-148. (10.2174/1874091X01812010130)
- Kandil, S., Prencipe, F., Jones, S., Hiscox, S. and Westwell, A. D. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91(1), pp. 314-321. (10.1111/cbdd.13083)
2016
- Wymant, J., Hiscox, S., Westwell, A., Urbe, S., Clague, M. and Jones, A. T. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7(15), pp. 2388-2407. (10.7150/jca.15055)
- Jones, S., Smith, C., Hiscox, S. and Jiang, W. G. 2016. Targeting metastasis and cancer stem-like cells in triple negative breast cancer through inhibition of focal adhesion kinase [Poster Abstract]. Presented at: AACR 107th Annual Meeting 2016, New Orleans, LA, USA, 16-20 April 2016, Vol. 76. Vol. S14. pp. 4125., (10.1158/1538-7445.am2016-4125)
- Bellerby, R. et al. 2016. Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology 6, article number: 145. (10.3389/fonc.2016.00145)
- Gangadhara, S., Smith, C., Barrett-Lee, P. and Hiscox, S. 2016. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer 16(1), article number: 345. (10.1186/s12885-016-2377-z)
2015
- Elseginy, S. A., Lazaro, G., Nawwar, G. A. M., Amin, K. M., Hiscox, S. E. and Brancale, A. 2015. Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. Bioorganic and Medicinal Chemistry Letters 25(4), pp. 758-762. (10.1016/j.bmcl.2014.12.095)
- Wiggins, H. L., Wymant, J. M., Solfa, F., Hiscox, S. E., Taylor, K. M., Westwell, A. D. and Jones, A. T. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93(3), pp. 332-342. (10.1016/j.bcp.2014.12.014)
2013
- Lazaro, G. et al. 2013. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer 20(5), pp. 691-704. (10.1530/ERC-13-0019)
- Hogstrand, C., Kille, P., Ackland, M. L., Hiscox, S. E. and Taylor, K. M. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455(2), pp. 229-237. (10.1042/BJ20130483)
- Eccles, S. A. et al. 2013. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research 15(5), pp. R92. (10.1186/bcr3493)
2012
- Gangadhara, S., Barrett-Lee, P., Nicholson, R. and Hiscox, S. E. 2012. Pro-metastatic tumor-stroma interactions in breast cancer. Future Oncology 8(11), pp. 1427-1442. (10.2217/fon.12.134.)
- Hiscox, S. E. et al. 2012. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 12, article number: 458. (10.1186/1471-2407-12-458)
- Taylor, K. M., Hiscox, S. E., Nicholson, R. I., Hogstrand, C. and Kille, P. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5(210), article number: ra11. (10.1126/scisignal.2002585)
2011
- Hiscox, S. E., Barrett-Lee, P. and Nicholson, R. I. 2011. Therapeutic targeting of tumor–stroma interactions. Expert Opinion on Therapeutic Targets 15(5), pp. 609-621. (10.1517/14728222.2011.561201)
- Hiscox, S. E., Barnfather, P., Hayes, E. R., Bramble, P., Christensen, J., Nicholson, R. I. and Barrett-Lee, P. 2011. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Research and Treatment 125(3), pp. 659-669. (10.1007/s10549-010-0857-4)
- Davies, E. and Hiscox, S. E. 2011. New therapeutic approaches in breast cancer. Maturitas 68(2), pp. 121-128. (10.1016/j.maturitas.2010.10.012)
- Wadhawan, A., Smith, C., Nicholson, R. I., Barrett-Lee, P. and Hiscox, S. E. 2011. Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention. Cancer Treatment Reviews 37(3), pp. 234-241. (10.1016/j.ctrv.2010.08.003)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Hayes, E. R., Nicholson, R. I. and Hiscox, S. E. 2011. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Frontiers in Bioscience 16(1), pp. 838-848. (10.2741/3723)
2010
- Hiscox, S. E., Barrett-Lee, P., Borley, A. C. and Nicholson, R. I. 2010. Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss. European Journal of Cancer 46(12), pp. 2187-2195. (10.1016/j.ejca.2010.04.012)
- Weaver, B. P. et al. 2010. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. PLoS ONE 5(10), article number: e13158. (10.1371/journal.pone.0013158)
2009
- Hiscox, S. E., Barnfather, P., Hayes, E. R., Bramble, P., Christensen, J., Nicholson, R. I. and Barrett-Lee, P. 2009. Inhibition of Focal Adhesion Kinase Suppresses Adverse Features of Endocrine-Resistant Breast Cancer Cells and Improves Endocrine Response in ER plus , Endocrine-Sensitive Cells [Abstract]. Cancer Research 69(24:S1), pp. 3130. (10.1158/0008-5472.SABCS-09-3130)
- Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8(16), pp. 1550-1558. (10.4161/cbt.8.16.8954)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115(1), pp. 57-67. (10.1007/s10549-008-0058-6)
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Smith, C., Goddard, L., Gee, J. . M. W. and Nicholson, R. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer, pp. 139-160., (10.1007/978-1-4020-8526-0_8)
- Baruah, B. P., Barrett-Lee, P., Smith, C., Nicholson, R. I. and Hiscox, S. E. 2009. CD44-Activated HER-2 Signalling in Tamoxifen Resistant Breast Cancer Cells Promotes a Migratory Phenotype. Cancer Research 69(24), pp. 811S-811S.
- Baruah, B. P., Smith, C., Jordan, N. J., Nicholson, R. I., Robertson, J., Barrett-Lee, P. and Hiscox, S. E. 2009. Overexpression of CD44 in acquired endocrine resistant breast cancer modulates erbB activity and promotes an invasive phenotype. Cancer Research 69(2), pp. 811S-811S.
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Taylor, K. M. and Gee, J. M. W. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 1-26., (10.1007/978-1-4020-8526-0_1)
- Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
- Hiscox, S. E., Jordan, N. J., Crandon-Lewis, A., Jiang, W., Nicholson, R. I. and Gee, J. M. W. 2009. Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype [Abstract]. Cancer Research 69(2), pp. 213S-213S. (10.1158/0008-5472.SABCS-3028)
- Hiscox, S. E., Davies, E. and Barrett-Lee, P. 2009. Aromatase inhibitors in breast cancer. Maturitas 63(4), pp. 275-279. (10.1016/j.maturitas.2009.05.008)
- Wadhawan, A., Barrett-Lee, P., Smith, C., Nicholson, R. I. and Hiscox, S. E. 2009. Src-Dependent Changes in Beta-Catenin Activity Promote a Migratory Phenotype in Endocrine-Resistant Breast Cancer Cells. Cancer Research 69(24), pp. 813S.
- Hiscox, S. E. and Nicholson, R. I. 2009. Resistance to hormone therapy in breast cancer. Advances in Breast Cancer 6(3), pp. 2-6.
2008
- Taylor, K. M., Vichova, P., Jordan, N. J., Hiscox, S. E., Hendley, R. and Nicholson, R. I. 2008. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology 149(10), pp. 4912-4920. (10.1210/en.2008-0351)
- Hiscox, S. E., Goddard, L., Jordan, N. J., Smith, C., Harper, M. E., Nicholson, R. I. and Gee, J. M. W. 2008. Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1 [Abstract]. Breast Cancer Research 10(S2), article number: P34. (10.1186/bcr1918)
- Morgan, L. D., Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8(4), pp. 273-278. (10.2174/187153008786848295)
- Borley, A. C., Hiscox, S. E., Gee, J. M. W., Smith, C., Shaw, V., Barrett-Lee, P. and Nicholson, R. I. 2008. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Research 10(6), article number: R103. (10.1186/bcr2206)
- Hiscox, S. E. and Nicholson, R. I. 2008. Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets 12(6), pp. 757-767. (10.1517/14728220802133204)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
- Taylor, K. M., Jordan, N. J., Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10(s2), article number: P42. (10.1186/bcr1926)
2007
- Borley, A. C., Barrett-Lee, P., Gee, J. M. W., Show, V. E., Nicholson, R. and Hiscox, S. E. 2007. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Research and Treatment 106(Supp 1), pp. S7-S8.
- Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
- Khirwadkar, Y., Hiscox, S. E., Jordan, N. J. and Nicholson, R. I. 2007. HGF/SF promotes an aggressive phenotype in c-Met-overexpressing fulvestrant-resistant MCF-7 cells - Evidence for MMP-9 and PI3k involvement [Abstract]. Annals of Oncology 18(S4), article number: P611. (10.1093/annonc/mdm166)
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Green, T. P. and Nicholson, R. I. 2007. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical & Experimental Metastasis 24(3), pp. 157-167. (10.1007/s10585-007-9065-y)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S. E., Giles, M., Taylor, K. M. and Gee, J. M. W. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8(3), pp. 241-253. (10.1007/s11154-007-9033-5)
- Hiscox, S. E., Green, T. P., Smith, C., James, M., Jordan, N. J. and Nicholson, R. I. 2007. Combination treatment with AZD0530 and tamoxifen prevents acquired antiestrogen resistance in breast cancer cells [Abstract]. Molecular Cancer Therapeutics 6(Suppl), pp. 3411S.
2006
- Gee, J. M. W., Shaw, V. E., Hiscox, S. E., McClelland, R. A., Rushmere, N. K. and Nicholson, R. I. 2006. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer 13(S1), pp. S77-S88. (10.1677/erc.1.01274)
- Hiscox, S. E., Morgan, L. D., Green, T. and Nicholson, R. 2006. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 13, pp. S53-S59. (10.1677/erc.1.01297)
- Hiscox, S. E., Jordan, N. J., Jiang, W. G., Harper, M. E., McClelland, R., Smith, C. and Nicholson, R. 2006. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocrine-Related Cancer 13(4), pp. 1085-1099. (10.1677/erc.1.01270)
- Hiscox, S. E., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97(3), pp. 263-274. (10.1007/s10549-005-9120-9)
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118(2), pp. 290-301. (10.1002/ijc.21355)
- Hiscox, S. E., Green, T. P. and Nicholson, R. I. 2006. Combination therapy using AZD0530 and tamoxifen prevents antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 100(Supp 1), pp. S246-S246.
2005
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Taylor, K. M., Vichova, P., Hiscox, S. E. and Nicholson, R. 2005. Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters. Breast Cancer Research and Treatment 94(Supp 1), pp. S162-S162.
- Hiscox, S. E., Harper, M. E., Jiang, W. G., McClelland, R. and Nicholson, R. 2005. Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion. Breast Cancer Research and Treatment 94(Supp 1), pp. S161-S161.
2004
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Taylor, K. M., Hiscox, S. E. and Nicholson, R. 2004. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends in Endocrinology and Metabolism 15(10), pp. 461-463.
- Hiscox, S. E., Morgan, L. D., Barrow, D., Dutkowski, C. M., Wakeling, A. and Nicholson, R. I. 2004. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21(3), pp. 201-212. (10.1023/B:CLIN.0000037697.76011.1d)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
2003
- Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S171. (10.1023/A:1026252325164)
2002
- Hiscox, S. E., Hallett, M. B., Morgan, B. P. and Van Den Berg, C. W. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293(2), pp. 714-721. (10.1016/S0006-291X(02)00280-2)
2001
- Hiscox, S. E. and Van Den Berg, C. W. 2001. Characterisation of cell activation through cyt2 and cyt1 tail of MCP. Molecular Immunology 38(2-3), pp. 96-97.
- Parr, C., Davies, G., Hiscox, S. E., Nakamura, T., Matsumoto, K., Jiang, W. G. and Mansel, R. E. 2001. Inhibition of HGF/SF-induced cell-matrix adhesion, invasion, migration & paxillin phosphorylation, in prostate cancer by the HGF/SF antagonist, NK4. British Journal of Cancer 85(Supp 1), pp. 86-86. (10.1054/bjoc.2001.1918)
- Stephens, P., Hiscox, S. E., Cook, H., Jiang, W. G., Zhiquiang, W. and Thomas, D. W. 2001. Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts. Wound Repair and Regeneration 9(1), pp. 34-43. (10.1046/j.1524-475x.2001.00034.x)
2000
- Stead, P. et al. 2000. Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity. Biorganic and Medicinal Chemistry Letters 10(7), pp. 661-664.
- Parr, C., Hiscox, S. E., Nakamura, T., Matumoto, K. and Jiang, W. G. 2000. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. International Journal of Cancer 85(4), pp. 563-570. (10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D)
- Hiscox, S. E., Parr, C., Nakamura, T., Matsumoto, K., Jiang, W. G. and Mansel, R. E. 2000. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. British Journal of Cancer 59(3), pp. 245-254. (10.1023/A:1006348317841)
1999
- Jiang, W. G., Hiscox, S. E., Parr, C., Martin, T. A., Matsumoto, K., Nakamura, T. and Mansel, R. E. 1999. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clinical Cancer Research 5(11), pp. 3695-3703.
- Hiscox, S. E., Mansel, R. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell adhesion and motility and associates with intercellular junctional proteins in cancer cells. British Journal of Cancer 81(4), pp. 579-579. (10.1038/sj.bjc.6690733)
- Hiscox, S. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. Journal of Cell Science 112(18), pp. 3081-3090.
- Hiscox, S. E. and Jiang, W. G. 1999. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochemical and Biophysical Research Communications 261(2), pp. 406-411. (10.1006/bbrc.1999.1002)
- Jiang, W. G., Hiscox, S., Matsumoto, K. and Nakamura, T. 1999. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology 29(3), pp. 209-248.
- Hiscox, S. E. and Jiang, W. G. 1999. Hepatocyte growth factor scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Research 19(1A), pp. 509-517.
- Davies, G., Hiscox, S. E., Llaffafian, I., Jiang, W. G. and Mason, M. D. 1999. HGF/SF influences the interaction between APC, GSK3 beta and beta-catenin, its impact on cell adhesion and in vitro invasion in prostate cancer. British Journal of Cancer 80(Supp 2), pp. 36-36.
1998
- Hiscox, S. E., Davies, E. and Jiang, W. G. 1998. Up-regulation of the expression of hepatocyte growth factor activator (HGFA) in breast cancer. British Journal of Cancer 78(2), pp. 150-150. (10.1038/bjc.1998.457)
- Jiang, W. G., Hiscox, S. E., Bryce, R. P., Horrobin, D. F. and Mansel, R. E. 1998. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. British Journal of Cancer 77(5), pp. 731-738. (10.1038/bjc.1998.120)
- Jiang, W., Hiscox, S. E., Bryce, R. P., Horrobin, D. F. and Mansel, R. E. 1998. The effects of n-6 polyunsaturated fatty acids on the expression of metastasis suppressors in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids, Edinburgh, UK, 20-24 July 1997 Presented at Riemersma, R. A. et al. eds.The Fourth International Congress on Essential Fatty Acids and Eicosanoids : Invited Papers From the Fourth International Congress. Champaign, Ill: Amer Oil Chemists Society Press pp. 303-311.
- Thomas, D. W., Hiscox, S. E., Stephens, P. and Jiang, W. 1998. Phenotypic variation in HGF production and bioactivity between oral and skin fibroblasts. Journal of Dental Research 77(Supp 2), pp. 767-767. (10.1177/0022034598077S201)
- Jiang, W. G., Hiscox, S. E., Horrobin, D. F., Bryce, R. P. and Mansel, R. E. 1998. Essential fatty acids regulate the expression of tumour suppressor genes in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids, Edinburgh, UK, 20-24 July 1997 Presented at Riemersma, R. A. et al. eds.Essential fatty acids and eicosanoids: invited papers from the Fourth International Congress. Champaign, Illinois: AOCS Press pp. 303-311.
1997
- Jiang, W. G. et al. 1997. Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Clinical and Experimental Metastasis 15(6), pp. 593-602. (10.1023/A:1018435229087)
- Jiang, W. G. and Hiscox, S. E. 1997. beta-catenin-cell adhesion and beyond (review). International Journal of Oncology 11(3), pp. 635-641.
- Davies, E., Cochrane, R. A., Hiscox, S. E., Jiang, W. G., Sweetland, H. M. and Mansel, R. E. 1997. The role of desmoglein 2 and E-cadherin in the invasion and motility of human breast cancer cells. International Journal of Oncology 11(2), pp. 415-419.
- Jiang, W. G., Hiscox, S. E., Horrobin, D. F., Bryce, R. P. and Mansel, R. E. 1997. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochemical and Biophysical Research Communications 237(3), pp. 639-644. (10.1006/bbrc.1997.7154)
- Jiang, W. G. and Hiscox, S. E. 1997. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histology and Histopathology 12(2), pp. 537-555.
- Hiscox, S. E. and Jiang, W. G. 1997. Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. Biochemical and Biophysical Research Communications 233(1), pp. 1-5. (10.1006/bbrc.1997.6388)
- Jiang, W. G. and Hiscox, S. 1997. Quantification of tumour cell-endothelial cell attachment by 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI). Cancer Letters 112(2), pp. 209-217. (10.1016/S0304-3835(96)04573-9)
- Jiang, W. G. and Hiscox, S. 1997. Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Research 17, pp. 1349-1354.
- Hiscox, S. E., Hallett, M. B., Jiang, W. G., Puntis, M. C. A. and Nakamura, T. 1997. Expression of the HGF/SF Receptor, c-met, and its ligand in human colorectal cancers. Cancer Investigation 15(6), pp. 513-521. (10.3109/07357909709047592)
1996
- Jiang, W. G. and Hiscox, S. E. 1996. Cytokine regulation of ezrin expression in the human colon cancer cell line HT29.. Anticancer Research 16(2), pp. 861-865.
1995
- Jiang, W. G., Hiscox, S., Hallett, M. B., Horrobin, D., Mansel, R. E. and Puntis, M. 1995. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Research 55, pp. 5043-5048.
Articles
- Cai, S. et al. 2021. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. International Journal of Oncology 58(6), article number: 34. (10.3892/ijo.2021.5214)
- Rees, M., Smith, C., Barrett-Lee, P. and Hiscox, S. 2020. PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer. Oncotarget 11(51), pp. 4722-4734. (10.18632/oncotarget.27846)
- Kandil, S. B., Jones, S. R., Smith, S., Hiscox, S. E. and Westwell, A. D. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25(15), article number: 3488. (10.3390/molecules25153488)
- Ranganathan, P., Chakrabarty, A., Hiscox, S., Limaye, A. M. and Vella, V. 2020. Editorial: Resistance to endocrine therapies in cancer. Frontiers in Endocrinology 11, article number: 196. (10.3389/fendo.2020.00196)
- Davison, Z., Nicholson, R. I., Hiscox, S. and Heard, C. M. 2018. Co-administration of fish oil with signal transduction inhibitors has anti-migration effects in breast cancer cell lines, in vitro. The Open Biochemistry Journal 12(1), pp. 130-148. (10.2174/1874091X01812010130)
- Kandil, S., Prencipe, F., Jones, S., Hiscox, S. and Westwell, A. D. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91(1), pp. 314-321. (10.1111/cbdd.13083)
- Wymant, J., Hiscox, S., Westwell, A., Urbe, S., Clague, M. and Jones, A. T. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7(15), pp. 2388-2407. (10.7150/jca.15055)
- Bellerby, R. et al. 2016. Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology 6, article number: 145. (10.3389/fonc.2016.00145)
- Gangadhara, S., Smith, C., Barrett-Lee, P. and Hiscox, S. 2016. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer 16(1), article number: 345. (10.1186/s12885-016-2377-z)
- Elseginy, S. A., Lazaro, G., Nawwar, G. A. M., Amin, K. M., Hiscox, S. E. and Brancale, A. 2015. Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. Bioorganic and Medicinal Chemistry Letters 25(4), pp. 758-762. (10.1016/j.bmcl.2014.12.095)
- Wiggins, H. L., Wymant, J. M., Solfa, F., Hiscox, S. E., Taylor, K. M., Westwell, A. D. and Jones, A. T. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93(3), pp. 332-342. (10.1016/j.bcp.2014.12.014)
- Lazaro, G. et al. 2013. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer 20(5), pp. 691-704. (10.1530/ERC-13-0019)
- Hogstrand, C., Kille, P., Ackland, M. L., Hiscox, S. E. and Taylor, K. M. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455(2), pp. 229-237. (10.1042/BJ20130483)
- Eccles, S. A. et al. 2013. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research 15(5), pp. R92. (10.1186/bcr3493)
- Gangadhara, S., Barrett-Lee, P., Nicholson, R. and Hiscox, S. E. 2012. Pro-metastatic tumor-stroma interactions in breast cancer. Future Oncology 8(11), pp. 1427-1442. (10.2217/fon.12.134.)
- Hiscox, S. E. et al. 2012. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 12, article number: 458. (10.1186/1471-2407-12-458)
- Taylor, K. M., Hiscox, S. E., Nicholson, R. I., Hogstrand, C. and Kille, P. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5(210), article number: ra11. (10.1126/scisignal.2002585)
- Hiscox, S. E., Barrett-Lee, P. and Nicholson, R. I. 2011. Therapeutic targeting of tumor–stroma interactions. Expert Opinion on Therapeutic Targets 15(5), pp. 609-621. (10.1517/14728222.2011.561201)
- Hiscox, S. E., Barnfather, P., Hayes, E. R., Bramble, P., Christensen, J., Nicholson, R. I. and Barrett-Lee, P. 2011. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Research and Treatment 125(3), pp. 659-669. (10.1007/s10549-010-0857-4)
- Davies, E. and Hiscox, S. E. 2011. New therapeutic approaches in breast cancer. Maturitas 68(2), pp. 121-128. (10.1016/j.maturitas.2010.10.012)
- Wadhawan, A., Smith, C., Nicholson, R. I., Barrett-Lee, P. and Hiscox, S. E. 2011. Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention. Cancer Treatment Reviews 37(3), pp. 234-241. (10.1016/j.ctrv.2010.08.003)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
- Hayes, E. R., Nicholson, R. I. and Hiscox, S. E. 2011. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Frontiers in Bioscience 16(1), pp. 838-848. (10.2741/3723)
- Hiscox, S. E., Barrett-Lee, P., Borley, A. C. and Nicholson, R. I. 2010. Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss. European Journal of Cancer 46(12), pp. 2187-2195. (10.1016/j.ejca.2010.04.012)
- Weaver, B. P. et al. 2010. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. PLoS ONE 5(10), article number: e13158. (10.1371/journal.pone.0013158)
- Hiscox, S. E., Barnfather, P., Hayes, E. R., Bramble, P., Christensen, J., Nicholson, R. I. and Barrett-Lee, P. 2009. Inhibition of Focal Adhesion Kinase Suppresses Adverse Features of Endocrine-Resistant Breast Cancer Cells and Improves Endocrine Response in ER plus , Endocrine-Sensitive Cells [Abstract]. Cancer Research 69(24:S1), pp. 3130. (10.1158/0008-5472.SABCS-09-3130)
- Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8(16), pp. 1550-1558. (10.4161/cbt.8.16.8954)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115(1), pp. 57-67. (10.1007/s10549-008-0058-6)
- Baruah, B. P., Barrett-Lee, P., Smith, C., Nicholson, R. I. and Hiscox, S. E. 2009. CD44-Activated HER-2 Signalling in Tamoxifen Resistant Breast Cancer Cells Promotes a Migratory Phenotype. Cancer Research 69(24), pp. 811S-811S.
- Baruah, B. P., Smith, C., Jordan, N. J., Nicholson, R. I., Robertson, J., Barrett-Lee, P. and Hiscox, S. E. 2009. Overexpression of CD44 in acquired endocrine resistant breast cancer modulates erbB activity and promotes an invasive phenotype. Cancer Research 69(2), pp. 811S-811S.
- Hiscox, S. E., Jordan, N. J., Crandon-Lewis, A., Jiang, W., Nicholson, R. I. and Gee, J. M. W. 2009. Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype [Abstract]. Cancer Research 69(2), pp. 213S-213S. (10.1158/0008-5472.SABCS-3028)
- Hiscox, S. E., Davies, E. and Barrett-Lee, P. 2009. Aromatase inhibitors in breast cancer. Maturitas 63(4), pp. 275-279. (10.1016/j.maturitas.2009.05.008)
- Wadhawan, A., Barrett-Lee, P., Smith, C., Nicholson, R. I. and Hiscox, S. E. 2009. Src-Dependent Changes in Beta-Catenin Activity Promote a Migratory Phenotype in Endocrine-Resistant Breast Cancer Cells. Cancer Research 69(24), pp. 813S.
- Hiscox, S. E. and Nicholson, R. I. 2009. Resistance to hormone therapy in breast cancer. Advances in Breast Cancer 6(3), pp. 2-6.
- Taylor, K. M., Vichova, P., Jordan, N. J., Hiscox, S. E., Hendley, R. and Nicholson, R. I. 2008. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology 149(10), pp. 4912-4920. (10.1210/en.2008-0351)
- Hiscox, S. E., Goddard, L., Jordan, N. J., Smith, C., Harper, M. E., Nicholson, R. I. and Gee, J. M. W. 2008. Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1 [Abstract]. Breast Cancer Research 10(S2), article number: P34. (10.1186/bcr1918)
- Morgan, L. D., Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8(4), pp. 273-278. (10.2174/187153008786848295)
- Borley, A. C., Hiscox, S. E., Gee, J. M. W., Smith, C., Shaw, V., Barrett-Lee, P. and Nicholson, R. I. 2008. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Research 10(6), article number: R103. (10.1186/bcr2206)
- Hiscox, S. E. and Nicholson, R. I. 2008. Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets 12(6), pp. 757-767. (10.1517/14728220802133204)
- Taylor, K. M., Jordan, N. J., Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10(s2), article number: P42. (10.1186/bcr1926)
- Borley, A. C., Barrett-Lee, P., Gee, J. M. W., Show, V. E., Nicholson, R. and Hiscox, S. E. 2007. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Research and Treatment 106(Supp 1), pp. S7-S8.
- Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
- Khirwadkar, Y., Hiscox, S. E., Jordan, N. J. and Nicholson, R. I. 2007. HGF/SF promotes an aggressive phenotype in c-Met-overexpressing fulvestrant-resistant MCF-7 cells - Evidence for MMP-9 and PI3k involvement [Abstract]. Annals of Oncology 18(S4), article number: P611. (10.1093/annonc/mdm166)
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Green, T. P. and Nicholson, R. I. 2007. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical & Experimental Metastasis 24(3), pp. 157-167. (10.1007/s10585-007-9065-y)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S. E., Giles, M., Taylor, K. M. and Gee, J. M. W. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8(3), pp. 241-253. (10.1007/s11154-007-9033-5)
- Hiscox, S. E., Green, T. P., Smith, C., James, M., Jordan, N. J. and Nicholson, R. I. 2007. Combination treatment with AZD0530 and tamoxifen prevents acquired antiestrogen resistance in breast cancer cells [Abstract]. Molecular Cancer Therapeutics 6(Suppl), pp. 3411S.
- Gee, J. M. W., Shaw, V. E., Hiscox, S. E., McClelland, R. A., Rushmere, N. K. and Nicholson, R. I. 2006. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer 13(S1), pp. S77-S88. (10.1677/erc.1.01274)
- Hiscox, S. E., Morgan, L. D., Green, T. and Nicholson, R. 2006. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 13, pp. S53-S59. (10.1677/erc.1.01297)
- Hiscox, S. E., Jordan, N. J., Jiang, W. G., Harper, M. E., McClelland, R., Smith, C. and Nicholson, R. 2006. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocrine-Related Cancer 13(4), pp. 1085-1099. (10.1677/erc.1.01270)
- Hiscox, S. E., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97(3), pp. 263-274. (10.1007/s10549-005-9120-9)
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118(2), pp. 290-301. (10.1002/ijc.21355)
- Hiscox, S. E., Green, T. P. and Nicholson, R. I. 2006. Combination therapy using AZD0530 and tamoxifen prevents antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 100(Supp 1), pp. S246-S246.
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Taylor, K. M., Vichova, P., Hiscox, S. E. and Nicholson, R. 2005. Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters. Breast Cancer Research and Treatment 94(Supp 1), pp. S162-S162.
- Hiscox, S. E., Harper, M. E., Jiang, W. G., McClelland, R. and Nicholson, R. 2005. Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion. Breast Cancer Research and Treatment 94(Supp 1), pp. S161-S161.
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Taylor, K. M., Hiscox, S. E. and Nicholson, R. 2004. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends in Endocrinology and Metabolism 15(10), pp. 461-463.
- Hiscox, S. E., Morgan, L. D., Barrow, D., Dutkowski, C. M., Wakeling, A. and Nicholson, R. I. 2004. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21(3), pp. 201-212. (10.1023/B:CLIN.0000037697.76011.1d)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S171. (10.1023/A:1026252325164)
- Hiscox, S. E., Hallett, M. B., Morgan, B. P. and Van Den Berg, C. W. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293(2), pp. 714-721. (10.1016/S0006-291X(02)00280-2)
- Hiscox, S. E. and Van Den Berg, C. W. 2001. Characterisation of cell activation through cyt2 and cyt1 tail of MCP. Molecular Immunology 38(2-3), pp. 96-97.
- Parr, C., Davies, G., Hiscox, S. E., Nakamura, T., Matsumoto, K., Jiang, W. G. and Mansel, R. E. 2001. Inhibition of HGF/SF-induced cell-matrix adhesion, invasion, migration & paxillin phosphorylation, in prostate cancer by the HGF/SF antagonist, NK4. British Journal of Cancer 85(Supp 1), pp. 86-86. (10.1054/bjoc.2001.1918)
- Stephens, P., Hiscox, S. E., Cook, H., Jiang, W. G., Zhiquiang, W. and Thomas, D. W. 2001. Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts. Wound Repair and Regeneration 9(1), pp. 34-43. (10.1046/j.1524-475x.2001.00034.x)
- Stead, P. et al. 2000. Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity. Biorganic and Medicinal Chemistry Letters 10(7), pp. 661-664.
- Parr, C., Hiscox, S. E., Nakamura, T., Matumoto, K. and Jiang, W. G. 2000. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. International Journal of Cancer 85(4), pp. 563-570. (10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D)
- Hiscox, S. E., Parr, C., Nakamura, T., Matsumoto, K., Jiang, W. G. and Mansel, R. E. 2000. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. British Journal of Cancer 59(3), pp. 245-254. (10.1023/A:1006348317841)
- Jiang, W. G., Hiscox, S. E., Parr, C., Martin, T. A., Matsumoto, K., Nakamura, T. and Mansel, R. E. 1999. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clinical Cancer Research 5(11), pp. 3695-3703.
- Hiscox, S. E., Mansel, R. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell adhesion and motility and associates with intercellular junctional proteins in cancer cells. British Journal of Cancer 81(4), pp. 579-579. (10.1038/sj.bjc.6690733)
- Hiscox, S. E. and Jiang, W. G. 1999. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. Journal of Cell Science 112(18), pp. 3081-3090.
- Hiscox, S. E. and Jiang, W. G. 1999. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochemical and Biophysical Research Communications 261(2), pp. 406-411. (10.1006/bbrc.1999.1002)
- Jiang, W. G., Hiscox, S., Matsumoto, K. and Nakamura, T. 1999. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology 29(3), pp. 209-248.
- Hiscox, S. E. and Jiang, W. G. 1999. Hepatocyte growth factor scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Research 19(1A), pp. 509-517.
- Davies, G., Hiscox, S. E., Llaffafian, I., Jiang, W. G. and Mason, M. D. 1999. HGF/SF influences the interaction between APC, GSK3 beta and beta-catenin, its impact on cell adhesion and in vitro invasion in prostate cancer. British Journal of Cancer 80(Supp 2), pp. 36-36.
- Hiscox, S. E., Davies, E. and Jiang, W. G. 1998. Up-regulation of the expression of hepatocyte growth factor activator (HGFA) in breast cancer. British Journal of Cancer 78(2), pp. 150-150. (10.1038/bjc.1998.457)
- Jiang, W. G., Hiscox, S. E., Bryce, R. P., Horrobin, D. F. and Mansel, R. E. 1998. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. British Journal of Cancer 77(5), pp. 731-738. (10.1038/bjc.1998.120)
- Thomas, D. W., Hiscox, S. E., Stephens, P. and Jiang, W. 1998. Phenotypic variation in HGF production and bioactivity between oral and skin fibroblasts. Journal of Dental Research 77(Supp 2), pp. 767-767. (10.1177/0022034598077S201)
- Jiang, W. G. et al. 1997. Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Clinical and Experimental Metastasis 15(6), pp. 593-602. (10.1023/A:1018435229087)
- Jiang, W. G. and Hiscox, S. E. 1997. beta-catenin-cell adhesion and beyond (review). International Journal of Oncology 11(3), pp. 635-641.
- Davies, E., Cochrane, R. A., Hiscox, S. E., Jiang, W. G., Sweetland, H. M. and Mansel, R. E. 1997. The role of desmoglein 2 and E-cadherin in the invasion and motility of human breast cancer cells. International Journal of Oncology 11(2), pp. 415-419.
- Jiang, W. G., Hiscox, S. E., Horrobin, D. F., Bryce, R. P. and Mansel, R. E. 1997. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochemical and Biophysical Research Communications 237(3), pp. 639-644. (10.1006/bbrc.1997.7154)
- Jiang, W. G. and Hiscox, S. E. 1997. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histology and Histopathology 12(2), pp. 537-555.
- Hiscox, S. E. and Jiang, W. G. 1997. Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. Biochemical and Biophysical Research Communications 233(1), pp. 1-5. (10.1006/bbrc.1997.6388)
- Jiang, W. G. and Hiscox, S. 1997. Quantification of tumour cell-endothelial cell attachment by 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI). Cancer Letters 112(2), pp. 209-217. (10.1016/S0304-3835(96)04573-9)
- Jiang, W. G. and Hiscox, S. 1997. Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Research 17, pp. 1349-1354.
- Hiscox, S. E., Hallett, M. B., Jiang, W. G., Puntis, M. C. A. and Nakamura, T. 1997. Expression of the HGF/SF Receptor, c-met, and its ligand in human colorectal cancers. Cancer Investigation 15(6), pp. 513-521. (10.3109/07357909709047592)
- Jiang, W. G. and Hiscox, S. E. 1996. Cytokine regulation of ezrin expression in the human colon cancer cell line HT29.. Anticancer Research 16(2), pp. 861-865.
- Jiang, W. G., Hiscox, S., Hallett, M. B., Horrobin, D., Mansel, R. E. and Puntis, M. 1995. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Research 55, pp. 5043-5048.
Book sections
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Smith, C., Goddard, L., Gee, J. . M. W. and Nicholson, R. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer, pp. 139-160., (10.1007/978-1-4020-8526-0_8)
- Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Taylor, K. M. and Gee, J. M. W. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 1-26., (10.1007/978-1-4020-8526-0_1)
- Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
- Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.
Conferences
- Jones, S., Smith, C., Hiscox, S. and Jiang, W. G. 2016. Targeting metastasis and cancer stem-like cells in triple negative breast cancer through inhibition of focal adhesion kinase [Poster Abstract]. Presented at: AACR 107th Annual Meeting 2016, New Orleans, LA, USA, 16-20 April 2016, Vol. 76. Vol. S14. pp. 4125., (10.1158/1538-7445.am2016-4125)
- Jiang, W., Hiscox, S. E., Bryce, R. P., Horrobin, D. F. and Mansel, R. E. 1998. The effects of n-6 polyunsaturated fatty acids on the expression of metastasis suppressors in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids, Edinburgh, UK, 20-24 July 1997 Presented at Riemersma, R. A. et al. eds.The Fourth International Congress on Essential Fatty Acids and Eicosanoids : Invited Papers From the Fourth International Congress. Champaign, Ill: Amer Oil Chemists Society Press pp. 303-311.
- Jiang, W. G., Hiscox, S. E., Horrobin, D. F., Bryce, R. P. and Mansel, R. E. 1998. Essential fatty acids regulate the expression of tumour suppressor genes in cancer cells. Presented at: Fourth International Congress on Essential Fatty Acids and Eicosanoids, Edinburgh, UK, 20-24 July 1997 Presented at Riemersma, R. A. et al. eds.Essential fatty acids and eicosanoids: invited papers from the Fourth International Congress. Champaign, Illinois: AOCS Press pp. 303-311.
Research
Research interests
Having previously trained in the field of cancer metastasis, my research interests are concerned with studying how tumour cells develop a metastatic phenotype, how drug resistance contributes to this process and exploring the role of the tumour microenvironment as a modulator of such behaviour. The goal of these studies is to reveal clinical markers of drug response/relapse and clinical targets through which tumour spread can be repressed.
- Breast cancer and acquired drug resistance
- Tumour invasion and metastasis
- Influence of the tumour microenvironment in tumour progression and spread
Acquired drug resistance
My research is concerned with characterisation of the molecular mechanisms associated with resistance to endocrine therapies using in vitro systems modelling relapse on anti-oestrogens. I have a particular interest in studying antihormone-induced alterations in signal transduction pathways which promote an adverse cell phenotype and may contribute to tumour progression in vivo. These studies will reveal potential biomarkers for therapeutic response in addition to highlighting signalling elements which may be targeted alongside existing endocrine therapies to improve response.
Current project include (i) exploring the role of CD44 in anti-hormone resistant breast cancer where it may augment the cells' response to erbB receptor ligands and (ii) the potential of targeting Src alongside the oestrogen receptor as a means to prevent acquired anti-oestrogen resistance.
Tumour invasion and metastasis
Tumour metastasis, a complex series of steps in which cancer cells leave their original site and migrate to other parts of the body via the host circulatory systems, is the single most important factor affecting the survival of a cancer patient. Unfortunately, despite an increasing variety of anticancer agents employed to treat such cancers, they are rarely curative.
My interests are currently concerned with (i) deciphering intracellular signalling pathways which regulate tumour cell adhesion, migration and invasion and enhance the tumour cells' metastatic potential and (ii) identifying key regulatory elements within these pathways which present potential therapeutic targets.
Tumour microenvironment
The interplay between tumour cells and their surrounding microenvironment (stromal cells, extracellular matrix) plays an important role in tumour development and progression.
Currently, I am investigating (i) how stromal cells can modulate the angiogenic capacity of tumour cells, (ii) how the c-met receptor, overexpressed in drug-resistant breast cancer, influences the cells' response to stromally-produced HGF/SF and (iii) how the tumour microenvironment can alter cell sensitivity to anticancer drugs.
Collaborators
Postdoctoral research associates
- Dr Nicola Jordan (funded by AstraZeneca)
School of Pharmacy and Pharmaceutical Sciences
- Professor Robert Nicholson
- Dr Julia Gee
Teaching
- PH1121 Molecule to patient
- PH1122 The role of the pharmacist in professional practice
- PH1123 Structure and function of cells and microbes
- PH3101 Optimisation of drug design
- PH3110 Optimisation of pharmaceutical care
- PH3202 Research methodology
- PH4116 Pharmacy research or scholarship project
- PH4118 Pharmaceutical sciences, pharmacy practice and the patient
Biography
Professional memberships
I am currently a member of the Executive Committee for the British Association for Cancer Research, a charitable organisation of over 1000 cancer professionals, and a member of the PhD Grants Panel for the Wales Office of Research and Development for Health and Social Care.